HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation
Cancer Treatment and Research Communications · 2026 · 48 · 101278
DOI: 10.1016/j.ctarc.2026.101278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Ki Hong Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, South Korea. Hauptthemen laut MEDLINE: Seminoma, Testicular Neoplasms, Hepatitis A Virus Cellular Receptor 2, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Soonchunhyang University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, South Korea.
- Department of Pathology, College of Medicine, Chung-Ang University, Seoul, South Korea.
- Department of Urology, Gimpo Woori Hospital, Gimpo, South Korea.
- Department of Pathology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, South Korea. Electronic address: whui01@schmc.ac.kr.
- Department of Urology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, South Korea. Electronic address: ysurol@schmc.ac.kr.
Förderung
- Soonchunhyang University
Zitieren
APA
Kim, K. H., Lee, D. Y., Yang, H. J., Kim, S. H., Kim, D. S., Lee, C. H., Hong, S. A., Chi, B. H., Lee, J. H., & Jeon, Y. S. (2026). HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation. Cancer Treatment and Research Communications, 48, 101278. https://doi.org/10.1016/j.ctarc.2026.101278
Vancouver
Kim KH, Lee DY, Yang HJ, Kim SH, Kim DS, Lee CH, et al. HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation. Cancer Treatment and Research Communications. 2026;48:101278. doi:10.1016/j.ctarc.2026.101278
BibTeX
@article{Kim2026,
author = {Kim, Ki Hong and Lee, Dae Young and Yang, Hee Jo and Kim, Si Hyun and Kim, Doo Sang and Lee, Chang Ho and Hong, Soon Auck and Chi, Byung Hoon and Lee, Ji-Hye and Jeon, Youn Soo},
title = {HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {48},
pages = {101278},
doi = {10.1016/j.ctarc.2026.101278}
}
EUVIMED